Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Wolinsky

Showing results (281-290 of 331) with videos related to

Pageof 34
Sort By:
Annals of Neurology|February 19, 2013
Chronic cerebrospinal venous insufficiency: case-control neurosonography resultsAndrew D Barreto, Staley A Brod, Thanh-Tung Bui, et al.
Journal of Neurology|July 16, 2013
Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid usePaul W O'Connor, Fred D Lublin, Jerry S Wolinsky, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 6, 2013
Chronic cerebrospinal venous insufficiency: masked multimodal imaging assessmentStaley A Brod, Larry A Kramer, Alan M Cohen, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 30, 2000
Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study GroupK P Johnson, B R Brooks, C C Ford, et al.
Neurology|September 6, 2019
Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosisFrederik Barkhof, Ludwig Kappos, Jerry S Wolinsky, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 8, 2022
Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMSDouglas L Arnold, Till Sprenger, Amit Bar-Or, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 11, 2003
Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trialK P Johnson, B R Brooks, C C Ford, et al.
The Lancet. Neurology|November 23, 2020
Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trialBruce A C Cree, Gary Cutter, Jerry S Wolinsky, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 4, 2024
Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-studyXavier Montalban, Karolina Piasecka-Stryczynska, Jens Kuhle, et al.
The Lancet. Neurology|November 1, 2020
Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trialJerry S Wolinsky, Douglas L Arnold, Bruno Brochet, et al.
Pageof 34

Showing results (281-290 of 331) with videos related to

Sort By:
Pageof 34
Annals of Neurology|February 19, 2013
Chronic cerebrospinal venous insufficiency: case-control neurosonography resultsAndrew D Barreto, Staley A Brod, Thanh-Tung Bui, et al.
Journal of Neurology|July 16, 2013
Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid usePaul W O'Connor, Fred D Lublin, Jerry S Wolinsky, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 6, 2013
Chronic cerebrospinal venous insufficiency: masked multimodal imaging assessmentStaley A Brod, Larry A Kramer, Alan M Cohen, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 30, 2000
Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study GroupK P Johnson, B R Brooks, C C Ford, et al.
Neurology|September 6, 2019
Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosisFrederik Barkhof, Ludwig Kappos, Jerry S Wolinsky, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 8, 2022
Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMSDouglas L Arnold, Till Sprenger, Amit Bar-Or, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 11, 2003
Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trialK P Johnson, B R Brooks, C C Ford, et al.
The Lancet. Neurology|November 23, 2020
Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trialBruce A C Cree, Gary Cutter, Jerry S Wolinsky, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 4, 2024
Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-studyXavier Montalban, Karolina Piasecka-Stryczynska, Jens Kuhle, et al.
The Lancet. Neurology|November 1, 2020
Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trialJerry S Wolinsky, Douglas L Arnold, Bruno Brochet, et al.
Pageof 34